SCHEMBL30104402

SCHEMBL30104402

CC(C)n1cc(-c2nc3c(-c4ccc5c(c4)CCCCC5N)ccnc3[nH]2)cn1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 14/20 0.48
▸ KCNH2 Q12809 1/20 0.38
▸ LRRK2 Q5S007 2/20 0.36
▸ MAP4K1 Q92918 1/20 0.35
▸ CD69 Q07108 1/20 0.35
▸ AURKA O14965 1/20 0.34
▸ FGR P09769 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ MINK1 Q8N4C8 1/20 0.34
▸ AXL P30530 2/20 0.34
▸ TYRO3 Q06418 2/20 0.34
▸ MERTK Q12866 2/20 0.34
▸ TTK P33981 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30104418 0.99 BTK (0.48) BTKKCNH2LRRK2MAP4K1CD69
SCHEMBL21776995 0.97 BTK (0.51) BTKKCNH2LRRK2MAP4K1AXL
Hydrochloric Acid SCHEMBL28591161 0.97 BTK (0.50) BTKKCNH2LRRK2MAP4K1AXL
Hydrochloric Acid SCHEMBL28593369 0.89 BTK (0.46) BTKKCNH2CD69CYP2C9
Hydrochloric Acid SCHEMBL30104456 0.86 BTK (0.48) BTKKCNH2CD69AURKACYP2C9
SCHEMBL21776936 0.86 BTK (0.49) BTKKCNH2CD69AURKAFGR
Hydrochloric Acid SCHEMBL30104462 0.86 BTK (0.43) BTKKCNH2
Hydrochloric Acid SCHEMBL30104450 0.85 BTK (0.48) BTKKCNH2CD69AURKAFGR
SCHEMBL21776742 0.84 BTK (0.49) BTKKCNH2CD69AURKAFGR
Hydrochloric Acid SCHEMBL30104414 0.84 BTK (0.48) BTKKCNH2CD69AURKAFGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415803-B2 Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) MERCK PATENT GMBH (DE) 2025-09-16 — — US disclosed
US-20220389004-A1 FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) EMD Serono Research and Development Institute, Inc. 2022-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415803-B2 Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) BTK, SYK, ABL1 BTK 1/4885KCNH2 2077/4885LRRK2 465/4885
US-20220389004-A1 FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) BTK, SYK, ABL1 BTK 1/4885KCNH2 2077/4885LRRK2 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback